Macugen Solution For Injection 0.3Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Macugen: Solution for injection (0.3mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

PEGAPTANIB (peg AP ta nib) is a drug that is injected into the eye. It is used to treat macular degeneration. This treatment results in a slowing of the disease and helps to maintain vision. It is not a cure.

In-Depth Information

Macugen Solution for Injection

NDC: 687820001
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Macular Degeneration

Sometimes used for but not FDA approved for the following conditions:
Diabetic Retinopathy, Diabetic Macular Edema

Storage Information
Refrigerate (between 36 and 46 degrees F)
Protect from freezing
Macugen Solution for Injection

Reported Side Effects for Macugen Solution for Injection

Retinal Detachment Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Endophthalmitis Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Brain Attack Incidence:
1.0-5.0%*
Severity: SEVERE
Onset: EARLY
Vomiting Incidence:
1.0-5.0%*
Severity: MILD
Onset: EARLY
Heart Attack Incidence:
1.0-5.0%*
Severity: SEVERE
Onset: DELAYED
Chest Pain Incidence:
1.0-5.0%*
Severity: MODERATE
Onset: EARLY
Balance Problems Incidence:
1.0-5.0%*
Severity: MILD
Onset: EARLY
Retaining Urine Incidence:
1.0-5.0%*
Severity: MODERATE
Onset: EARLY
Fluid Around The Lungs Incidence:
1.0-5.0%*
Severity: SEVERE
Onset: DELAYED
Corneal Deposits Incidence:
1.0-5.0%*
Severity: MODERATE
Onset: DELAYED
Deafness Incidence:
1.0-5.0%*
Severity: SEVERE
Onset: DELAYED
Large Pupil Incidence:
1.0-5.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
1.0-5.0%*
Severity: MILD
Onset: EARLY
Retinal Edema Incidence:
1.0-5.0%*
Severity: SEVERE
Onset: DELAYED
Diabetes Incidence:
1.0-5.0%*
Severity: MODERATE
Onset: DELAYED
Allergic Skin Reaction Incidence:
1.0-5.0%*
Severity: MODERATE
Onset: DELAYED
Conjunctivitis Incidence:
6.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Lightheadedness Incidence:
6.0-10.0%*
Severity: MILD
Onset: EARLY
Photopsia Incidence:
6.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Upset Stomach Incidence:
6.0-10.0%*
Severity: MILD
Onset: EARLY
Inflamed Eyes Incidence:
6.0-10.0%*
Severity: MODERATE
Onset: EARLY
Loose Stools Incidence:
6.0-10.0%*
Severity: MILD
Onset: EARLY
Headache Incidence:
6.0-10.0%*
Severity: MILD
Onset: EARLY
Infection Incidence:
6.0-10.0%*
Severity: MILD
Onset: DELAYED
Eye Infection Incidence:
6.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Cataracts Incidence:
10.0-40.0%*
Severity: MODERATE
Onset: DELAYED
Eye Pain Incidence:
10.0-40.0%*
Severity: MILD
Onset: EARLY
Eye Inflammation Incidence:
10.0-40.0%*
Severity: MODERATE
Onset: EARLY
Corneal Edema Incidence:
10.0-40.0%*
Severity: MODERATE
Onset: EARLY
High Eye Blood Pressure Incidence:
10.0-40.0%*
Severity: SEVERE
Onset: DELAYED
Eye Inflammatoin Incidence:
10.0-40.0%*
Severity: SEVERE
Onset: DELAYED
High Blood Pressure Incidence:
10.0-40.0%*
Severity: MODERATE
Onset: EARLY
Bleeding Within The Eye Incidence:
10.0-40.0%*
Severity: SEVERE
Onset: DELAYED
Eye Irritation Incidence:
10.0-40.0%*
Severity: MILD
Onset: RAPID
Blurred Vision Incidence:
10.0-40.0%*
Severity: MODERATE
Onset: EARLY
Visual Impairment Incidence:
10.0-40.0%*
Severity: SEVERE
Onset: EARLY
Eye Drainage Incidence:
10.0-40.0%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Macugen

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5